Hansoh Pharma Receives NMPA Clearance for HS-10582 Phase I Clinical Trials in Hypercholesterolemia

Bulletin Express

Aug 06

Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that China’s National Medical Products Administration (NMPA) has granted Clinical Trial Approval for HS-10582 tablets, the group’s self-developed Class 1 innovative medicine. The upcoming study will evaluate the drug’s safety and efficacy in adult patients with primary hypercholesterolemia and mixed dyslipidemia.

The Board, chaired by Zhong Huijuan, disclosed the regulatory milestone on 6 August 2026. HS-10582’s approval underscores the company’s continued progress in expanding its cardiovascular-metabolic pipeline through internally developed assets.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1147648427"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1147648427\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1147648427?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1147648427","market":"hk","top_or_hot":-1,"title":"Hansoh Pharma Receives NMPA Clearance for HS-10582 Phase I Clinical Trials in Hypercholesterolemia","media":"Bulletin Express","content":"<p>Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that China’s National Medical Products Administration (NMPA) has granted Clinical Trial Approval for HS-10582 tablets, the group’s self-developed Class 1 innovative medicine. The upcoming study will evaluate the drug’s safety and efficacy in adult patients with primary hypercholesterolemia and mixed dyslipidemia.</p>\n<p>The Board, chaired by Zhong Huijuan, disclosed the regulatory milestone on 6 August 2026. HS-10582’s approval underscores the company’s continued progress in expanding its cardiovascular-metabolic pipeline through internally developed assets.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharma Receives NMPA Clearance for HS-10582 Phase I Clinical Trials in Hypercholesterolemia</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharma Receives NMPA Clearance for HS-10582 Phase I Clinical Trials in Hypercholesterolemia\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-06 19:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that China’s National Medical Products Administration (NMPA) has granted Clinical Trial Approval for HS-10582 tablets, the group’s self-developed Class 1 innovative medicine. The upcoming study will evaluate the drug’s safety and efficacy in adult patients with primary hypercholesterolemia and mixed dyslipidemia.</p>\n<p>The Board, chaired by Zhong Huijuan, disclosed the regulatory milestone on 6 August 2026. HS-10582’s approval underscores the company’s continued progress in expanding its cardiovascular-metabolic pipeline through internally developed assets.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1147648427","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1147648427","pubTimestamp":1786014372,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that China’s National Medical Products Administration (NMPA) has granted Clinical Trial Approval for HS-10582 tablets, the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"豪森制药HS-10582治疗高胆固醇血症I期临床试验获NMPA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma) announced that China’s National Medical Products Administration (NMPA) has granted Clinical Trial Approval for HS-10582 tablets, the group’s self-developed Class 1 innovative medicine. The upcoming study will evaluate the drug’s safety and efficacy in adult patients with primary hypercholesterolemia and mixed dyslipidemia.\nThe Board, chaired by Zhong Huijuan, disclosed the regulatory milestone on 6 August 2026. HS-10582’s approval underscores the company’s continued progress in expanding its cardiovascular-metabolic pipeline through internally developed assets.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}